• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Routine Induction for Women 35 and Older – Are there Associated Risks?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Data on nonmedically indicated induction in women ≥ 35 years compared to expectant management broken down by gestational weeks is limited  
  • Kawakita et al. (American Journal of Perinatology, 2018) compared maternal and neonatal outcomes in women aged ≥ 35 years who had nonmedically indicated induction of labor (NMII) versus expectant management 

METHODS: 

  • Retrospective cohort study  
  • Participants: Nulliparous women with a singleton and cephalic presentation who delivered at term 
  • Data derived from Consortium on Safe Labor (2002 and 2008) in 12 clinical centers/19 hospitals, supported by NICHD grant 
    • Data abstraction from medical records with rigorous data checking  
  • Nonmedically indicated induction (NMII) 
    • No medical maternal/fetal disorder or PROM  
  • Women were stratified into groups based on gestational week  
    • NMII at 37 weeks  
    • NMII at 38 weeks  
    • NMII at 39 weeks  
    • NMII at 40 weeks  
    • Those expectant management that week  
  • Maternal and neonatal outcomes (individual and composite) were evaluated 
  • Study not powered to assess rare adverse events such as stillbirth 

RESULTS: 

  • 3819 women were included in the study 
    • 1409 (36.9%) women underwent NMII 
  • No statistically differences in composite maternal outcomes at any gestational age  
  • Overall, at 39 weeks’ gestation or later, maternal and neonatal outcomes were similar or improved with NMII 
  • At 37, 38, and 39 weeks’ gestation, NMII compared with expectant management was associated with decreased odds of cesarean delivery  
    • 37 weeks:  adjusted odds ratio (aOR) 0.52; 95% CI, 0.31–0.88 
    • 38 weeks: aOR 0.64; 95% CI, 0.45–0.91 
    • 39 weeks: aOR 0.69; 95% CI, 0.53–0.91 
  • At 40 weeks’ gestation, NMII compared with expectant management was associated with increased risk of operative vaginal delivery  
    • aOR, 2.43; 95% CI, 1.46–4.06  
  • 40 weeks induction also associated with decreased odds of neonatal intensive care unit (NICU) admission 
    • aOR, 0.40; 95% CI, 0.20–0.81 

CONCLUSION: 

  • Nonmedically indicated induction was correlated with decreased risk for cesarean delivery at 37 to 39 weeks gestation and at 40 weeks, with a decreased risk for NICU admission 

Learn More – Primary Sources: 

Nonmedically Indicated Induction of Labor Compared with Expectant Management in Nulliparous Women Aged 35 Years or Older 

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

A New Predictive Model for Successful Induction of Labor
Maternal Age: What is the Impact on Stillbirth and Other Adverse Pregnancy Outcomes?
Induction to Prevent Stillbirths for Age 35 and Older: Impact on Cesarean Rates?
Deliver Low Risk Patients at 39 Weeks to Prevent Hypertensive Complications?
Does Extending Pregnancy Beyond 39 weeks in Low-risk Pregnancies Incur Additional Risk?
The ARRIVE Trial and Professional Guidance: Elective 39 Week Induction to Reduce the Risk of Cesarean Section

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site